Investigational drug · Phase 3
ZX-7101A
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Respiratory Viral Infection.
Phase 3Last checked: Nov 20, 2026Latest source record: Feb 19, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
11
Any phase or sponsor naming "ZX-7101A"
First trial start
2023
Nov 30, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ZX-7101A", any sponsor or status.
Conditions studied
As listed on its trial records.
- Respiratory Viral Infection
Approved drugs for the same conditions: Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "ZX-7101A" as an intervention, largest first.
- A Study to Evaluate the Efficacy and Safety of ZX-7101A Tablets in Adults with Uncomplicated InfluenzaPivotal-lookingCompleted
Nanjing Zenshine PharmaceuticalsIndustry
NCT05702489 · 900 participants · Start Jul 17, 2022 · Primary completion May 26, 2023
Drug: ZX-7101A · For: Influenza, Human
Sites: Shanghai, China
- Study to Assess the Safety and Efficacy of ZX-7101A in Adolescents With InfluenzaPivotal-lookingCompleted
Nanjing Zenshine PharmaceuticalsIndustry
NCT06099873 · 361 participants · Start Nov 30, 2023 · Primary completion Feb 13, 2025
Drug: ZX-7101A; Placebo · For: Respiratory Viral Infection
Sites: Shanghai, China
- Study to Assess the Safety and Efficacy of ZX-7101A for Oral Suspension in Chinese Pediatric Participants 2 to 11 Years of Age With InfluenzaPivotal-lookingCompleted
Nanjing Zenshine PharmaceuticalsIndustry
NCT07095257 · 169 participants · Start Oct 13, 2025 · Primary completion Jan 16, 2026
Drug: ZX-7101A for oral suspension; Oseltamivir phosphate for oral suspension · For: Respiratory Viral Infection
Sites: Chengdu, China; Hangzhou, China
- Study to Assess the Safety and Efficacy of ZX-7101A in Children Aged 5-11 Years With InfluenzaPivotal-lookingTerminated
Nanjing Zenshine PharmaceuticalsIndustry
NCT06669351 · 98 participants · Start Oct 31, 2024 · Primary completion Jul 15, 2025
Drug: ZX-7101A; Oseltamivir phosphate dry suspension · For: Respiratory Viral Infection
Sites: Baoding, China; Chengdu, China; Hangzhou, China
Nanjing Zenshine PharmaceuticalsIndustry
NCT05217732 · 66 participants · Start Dec 1, 2021 · Primary completion Aug 29, 2022
Drug: ZX-7101A; Placebo · For: Safety Issues; Tolerance; Pharmacokinetics and 1 more
Sites: Shanghai, China
Nanjing Zenshine PharmaceuticalsIndustry
NCT06841926 · 40 participants · Start Feb 20, 2025 · Primary completion Apr 18, 2025
Drug: ZX-7101A dry suspension · For: Respiratory Viral Infection
Sites: Chengdu, China
Nanjing Zenshine PharmaceuticalsIndustry
NCT05955027 · 24 participants · Start Jul 8, 2023 · Primary completion Aug 5, 2023
Drug: ZX-7101A; Placebo · For: Influenza, Human
Sites: Shanghai, China
Nanjing Zenshine PharmaceuticalsIndustry
NCT06057103 · 18 participants · Start Aug 28, 2023 · Primary completion Dec 5, 2023
Drug: ZX-7101A; Oseltamivir and 5 more · For: Drug Interaction
Sites: Beijing, China
- Pharmacokinetic Characteristics of Subjects with Hepatic Insufficiency and Healthy SubjectsCompleted
Nanjing Zenshine PharmaceuticalsIndustry
NCT05711797 · 16 participants · Start Apr 12, 2023 · Primary completion Feb 6, 2024
Drug: ZX-7101A 80mg · For: Influenza, Human
Sites: Shanghai, China
Nanjing Zenshine PharmaceuticalsIndustry
NCT05949385 · 16 participants · Start Jul 2, 2023 · Primary completion Sep 23, 2023
Drug: ZX-7101A · For: Pharmacokinetics
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- From neuraminidase inhibitors to novel mechanisms: expanding therapeutic strategies against influenza.
Sun Y, Kunanusorn P, Tup KM, et al. · Front Cell Infect Microbiol 2026
- Antiviral strategies against H5N1: current options and emerging therapeutics.
Anastassopoulou C, Panagiotopoulos AP, Ranellou K, et al. · Infection 2026
- Effect of itraconazole on pharmacokinetics of ZX-7101A tablets in healthy Chinese subjects.
Wu J, Wang Y, Liu W, et al. · Front Pharmacol 2025
- Corrigendum to "Efficacy and safety of ZX-7101A, an inhibitor of influenza cap-dependent endonuclease, in adults with uncomplicated influenza: a randomized, double-blind, placebo-controlled phase 2/3 trial" [Clin Microbiol Infect 31 (2025) 274-281].
Wang H, Wang G, Gao Y, et al. · Clin Microbiol Infect 2025
- Efficacy and safety of ZX-7101A, an inhibitor of influenza cap-dependent endonuclease, in adults with uncomplicated influenza: a randomized, double-blind, placebo-controlled phase 2/3 trial.
Wang H, Wang G, Gao Y, et al. · Clin Microbiol Infect 2025
- Safety, tolerability, and pharmacokinetics of a novel anti-influenza agent ZX-7101A tablets in healthy chinese participants: A first-in-human phase I clinical study.
Wu J, Wei Q, Jin Y, et al. · Int J Antimicrob Agents 2025
Also in development for Respiratory Viral Infection
- AP1189Phase 23 trials
SynAct Pharma Aps · Rheumatoid Arthritis (RA), Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy, Severe Proteinuria Due to Idiopathic Membranous Nephropathy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.